Hero of a series of mystery novels by Dorothy Dunnett
POPULARITY
Categories
90 episodes with Johnson Johnson
39 episodes with Johnson Johnson
23 episodes with Johnson Johnson
19 episodes with Johnson Johnson
34 episodes with Johnson Johnson
34 episodes with Johnson Johnson
21 episodes with Johnson Johnson
9 episodes with Johnson Johnson
27 episodes with Johnson Johnson
31 episodes with Johnson Johnson
13 episodes with Johnson Johnson
31 episodes with Johnson Johnson
15 episodes with Johnson Johnson
12 episodes with Johnson Johnson
16 episodes with Johnson Johnson
30 episodes with Johnson Johnson
14 episodes with Johnson Johnson
10 episodes with Johnson Johnson
11 episodes with Johnson Johnson
6 episodes with Johnson Johnson
10 episodes with Johnson Johnson
13 episodes with Johnson Johnson
15 episodes with Johnson Johnson
8 episodes with Johnson Johnson
15 episodes with Johnson Johnson
7 episodes with Johnson Johnson
5 episodes with Johnson Johnson
7 episodes with Johnson Johnson
9 episodes with Johnson Johnson
12 episodes with Johnson Johnson
10 episodes with Johnson Johnson
3 episodes with Johnson Johnson
8 episodes with Johnson Johnson
13 episodes with Johnson Johnson
5 episodes with Johnson Johnson
7 episodes with Johnson Johnson
4 episodes with Johnson Johnson
4 episodes with Johnson Johnson
8 episodes with Johnson Johnson
18 episodes with Johnson Johnson
10 episodes with Johnson Johnson
4 episodes with Johnson Johnson
8 episodes with Johnson Johnson
5 episodes with Johnson Johnson
5 episodes with Johnson Johnson
10 episodes with Johnson Johnson
7 episodes with Johnson Johnson
8 episodes with Johnson Johnson
6 episodes with Johnson Johnson
16 episodes with Johnson Johnson
10 episodes with Johnson Johnson
8 episodes with Johnson Johnson
6 episodes with Johnson Johnson
4 episodes with Johnson Johnson
Pennsylvania Democrat Senator John Fetterman has changed his mind on the filibuster. Sen. Fetterman discusses where he differs from his party lines, including Democratic Socialist efforts around the country. Stephen Miran was appointed by President Trump to the Federal Reserve Board of Governors. Ahead of the central bank's two-day policy meeting, Miran discusses money supply, its relationship to inflation, and the future of United States monetary policy. He's expecting the Fed to hold rates steady. Plus, Sherwin-Williams has reported a quarterly beat, Johnson & Johnson has agreed to pay $5.5B to settle the talc lawsuits that have hung over the stock for years, Cracker Barrel is bringing in a new CEO, and YouTube and Peacock are teaming up. Stephen Miran - 18:31 Sen. John Fetterman - 34:04 In this episode: Stephen Miran, @SteveMiran John Fetterman, @SenFettermanPA Joe Kernen, @JoeSquawk Becky Quick, @BeckyQuick Cameron Costa, @CameronCostaNY Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Carl Quintanilla, Jim Cramer and David Faber led off the show with the extension of the chip sector sell-off as AI jitters sparked buying in other groups: The software sector among the tech winners, while the Dow received a boost from Coca-Cola — whose earnings beat sent the stock to a record high. Speaking of Dow components, Boeing CEO Kelly Ortberg joined the program to discuss the company's Q2 results and why the stock has slumped over the past twelve months. Also in focus: The anchors discussed where companies' AI capex budgets should fit into your investment strategy, Johnson & Johnson's $5.5 billion talc settlement, Meta-BlackRock AI data center partnership, Apple CEO Tim Cook and incoming CEO John Ternus on the red carpet. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Hello our Poison Friends! We are back to fill you in on some more shady deeds from Johnson & Johnson's past. We have another Pharma guest appearance in this one, because Amgen was also involved in the synthetic erythropoietin business. Erythropoietin is the hormone released by the kidneys that stimulates red blood cell production. RBCs are produced in the blood marrow within bones. It always amazes me how the various systems of the body team up to keep everything balanced. Unfortunately, anemia (low RBCs/hemoglobin) is a common issue with kidney diseases, those on dialysis, and cancer patients. As such, these pharmaceutical companies sought to create synthetic erythropoietin to sell to these groups of patients. They succeeded and the treatment made billions of dollars in sales over the years. Relieving the effects of anemia in those with these already taxing conditions sounds great, but there were a number of problems. As it turns out, an increase in the hormone (and RBCs as a result) can lead to clotting, strokes, and heart attacks. Even worse, one researcher called the drug Miracle-Gro for tumors. Hundreds of thousands of patients were likely killed as a result of the treatment and J&J's hiding of study results. Thank you to all of our listeners and supporters! We truly appreciate you all! Please feel free to leave a comment or send us a DM!Patreon:patreon.com/thepoisonersalmanacMerch-https://poisonersalmanac.com/The Poisoner's Almanac IG-https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==Poisoner's Almanac TT-https://www.tiktok.com/@poisonersalmanacp?_t=ZT-8wdYQyXhKbm&_r=1
Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies. Host: Michael S. Lloyd, MD, FHRS Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS Disclosures: M. Lloyd · Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other T. Baykaner · Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific · Research: NIH, Boston Scientific K. Ellenbogen · Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott · Royalty Income: Wiley-Blackwell, Elsevier
Host Charlie James previews his upcoming interview with South Carolina Democratic Senate candidate Dr. Annie Andrews before revisiting the state's legislative battle over making Ivermectin an over-the-counter medication. Despite the bill passing nearly unanimously in both the House and Senate, it was ultimately sent back to the Agricultural Committee and effectively killed by Representative Davey Hiatt. Drawing on research from Diane Hardy of the Mom and Pop Alliance of South Carolina, James reveals that Representative Hiatt's son, Lander Hiatt, is a registered lobbyist for the Pharmaceutical Research and Manufacturers of America (PhRMA). He suggests that the bill's sudden defeat may have been directly influenced by this deep-seated lobbying connection to major pharmaceutical companies like Pfizer and Johnson & Johnson.
Carl Quintanilla, Jim Cramer and David Faber led off the show with a "Faber Report": Sources tell David that Stripe and Advent International have jointly offered $60.50 per share to acquire PayPal, whose shares surged on that news. The anchors reacted to what Berkshire Hathaway Chairman Warren Buffett told CNBC's Becky Quick exclusively about investing in Alphabet. Speaking of exclusives, BlackRock CEO Larry Fink joined the program for a wide-ranging interview -- discussing earnings, the investment climate and the AI boom. Also in focus: An unexpected decline in June producer prices, Morgan Stanley and Johnson & Johnson earnings, IBM shares coming off their worst day ever, SpaceX shares trading near their IPO price. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Poolbeg Pharma (AIM:POLB) CEO Jeremy Skillington joined Proactive's Stephen Gunnion to discuss the dosing of the first patient in its TOPICAL clinical trial evaluating POLB-001 for the prevention of cytokine release syndrome in multiple myeloma patients receiving Johnson & Johnson's teclistamab. Poolbeg expects to enrol up to 30 patients and remains on track to deliver interim clinical data by the end of summer 2026. Skillington highlighted growing interest from additional UK investigators, which could accelerate enrolment as more sites come online. Beyond the trial, Poolbeg is in active partnering discussions with both pharma companies developing CRS-associated cancer therapies and supportive care firms, supported by a comprehensive virtual data room. A positive FDA pre-IND meeting and research covering US payers across approximately 75 million lives strengthen the commercial case. "Having these clinical milestones and clinical data coming through throughout the summer — that really is what triggers the significant interest and potential transactions when it comes to partnering discussions," Skillington said. For more interviews with leading companies, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #PoolbegPharma #POLB001 #JeremySkillington #MultipleMyeloma #Biotech #Pharma #ClinicalTrials #DrugDevelopment #CancerResearch #CytokineReleaseSyndrome #CRS #HealthcareInnovation #Investing #SmallCapStocks #ProactiveInvestors
In this week's episode of WSJ's Take On the Week, co-hosts Miriam Gottfried and Telis Demos preview earnings from Taiwan's flagship chip maker, TSMC. They also break down why this coming week's earnings from Johnson & Johnson, UnitedHealth Group and Abbott Laboratories won't do much to save healthcare from its negative earnings growth expectations. Then, Miriam and Telis are joined by Christine Short, head of research at Wall Street Horizon, which is part of the financial-services company TMX Group, to decode why analysts' corporate earnings expectations are reaching exuberant highs. They ask: How are companies achieving such strong results without massive revenue growth, and are those gains sustainable? Plus, Short explains how the AI buildout is reshaping corporate efficiency. They also discuss how companies like BJ's Wholesale, FedEx and Nike are managing tariff refunds and what that has meant for consumers. They talk about what to expect from this week's bank earnings, with JPMorgan, Goldman Sachs, Bank of America and others slated to report. Then the hosts examine the broader market's health and what the Late Earnings Report Index, or LERI, which tracks when companies report later than expected, might be signaling about future volatility. This is WSJ's Take On the Week where co-hosts Telis Demos, Heard on the Street's banking and money columnist, and Miriam Gottfried, WSJ's investing and wealth management reporter, cut through the noise and dive into markets, the economy and finance—the big trades, key players and business news ahead. Have an idea for a future guest or episode? How can we better help you take on the week? We'd love to hear from you. Email the show at takeontheweek@wsj.com. To watch the video version of this episode, visit our WSJ Podcasts YouTube channel or the video page of WSJ.com Further Reading Honey, I Shrank the Cash Flow Jet-Fuel Prices Have Plunged but Aren't Resulting in Much Lower Fares Meta Rakes It In, Yet Still Borrows Billions for AI For more coverage of the markets and your investments, head to WSJ.com, WSJ's Heard on The Street Column, and WSJ's Live Markets blog. Sign up for the WSJ's free Markets A.M. newsletter. Follow Miriam Gottfried here and Telis Demos here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm. Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy. Host: Michael S. Lloyd, MD, FHRS Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical
This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QSP865. CME/MOC/AAPA credit will be available until June 29, 2027.Continuing the Innovation Story in Prostate Cancer: Novel Advances and Therapeutic Expansions Across Disease Settings In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Prostate Net. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QEA865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Bladder Cancer Breakthroughs Unpacked: Practical Guidance on Bladder-Sparing Innovations, Perioperative Standards, and Multi-Targeted Platforms Across the Disease Spectrum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and World Bladder Cancer Patient Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from Astellas and Pfizer, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QSQ865. CME/MOC/AAPA/IPCE credit will be available until June 29, 2027.Innovation Takes the Stage in HNSCC: Immunotherapy and Novel Therapeutics in Locally Advanced and Recurrent/Metastatic Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Head and Neck Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through independent educational grants from AstraZeneca, AVEO Pharmaceuticals, Inc., Johnson & Johnson, and Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TPJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 29, 2027.Therapeutic Progress and IMPACT in CRC: Expert Guidance on Applying Rapidly Emerging Evidence on Immunotherapy and Molecular, Precision-Based Approaches in CRC Treatment In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Colorectal Cancer Alliance. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported through medical education grants from Bristol Myers Squibb, Exelixis, Inc., Johnson & Johnson, and Taiho Oncology, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAU865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2027.Real Talk on Directions and Decisions in the Clinical Management of EGFRm NSCLC: Optimizing the Patient Journey Throughout the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Black Diamond Therapeutics Inc, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
The most successful startups do not rely on luck. They build repeatable Legal Risk Systems that help prevent small mistakes from becoming expensive disasters. During Part 2 of our conversation with Phil Crowley, the discussion moved beyond business formation and into a broader challenge facing modern founders: how to manage legal risk in a world increasingly influenced by AI, automation, rapid growth, and limited resources. The lesson was simple but powerful. Legal protection should not be treated as an event. It should be treated as a system. Who Is Phil Crowley? Phil Crowley is the Founder and Managing Partner of Crowley Law LLC. Before launching his own practice, he spent approximately three decades as Assistant General Counsel at Johnson & Johnson, working closely with business leaders, innovators, and technology-focused organizations. His background is particularly unique because he began his professional career as a research physicist before transitioning into law. That combination enables him to bridge the communication gap that often exists between technical founders and legal professionals. Crowley now focuses on helping technology entrepreneurs commercialize innovation while avoiding common legal mistakes that can derail growth. Follow Phil on LinkedIn: https://www.linkedin.com/in/philcrowleynjny/ Legal Risk Systems Start with Process, Not Paperwork Many entrepreneurs believe legal work begins and ends with filing an LLC. That mindset creates blind spots. Legal protection requires ongoing processes that support the business as it evolves. Examples include: Contract review procedures Intellectual property audits Annual compliance reviews Founder agreement updates Vendor documentation These activities create consistency. Without systems, businesses rely on memory. And memory is unreliable. Businesses scale through systems. Risk management is no exception. Legal Risk Systems The AI Temptation One of the most interesting discussions centered on AI-generated legal content. Today, founders can ask an AI platform to generate: Contracts NDAs Service agreements Terms of service Business policies The convenience is undeniable. The risk is equally real. AI generates responses from patterns. It does not understand the specific context of your business. An agreement that worked for another company may be completely inappropriate for yours. Even worse, AI may surface examples that became popular because they were involved in legal disputes. Popularity does not equal quality. The Human Validation AI can accelerate research. It can assist with drafting. It can organize information. What it cannot do is replace professional legal judgment. The most effective workflow is: Use AI for research and preparation. Create a draft framework. Engage qualified legal counsel. Validate assumptions before execution. This approach improves efficiency without increasing unnecessary risk. AI can reduce drafting time, but cannot eliminate legal accountability. Building Relationships Instead of Buying Documents Another recurring theme was relationship-building. Many founders purchase legal templates and assume the problem is solved. The reality is different. Legal value comes from context. An attorney who understands your business can identify risks you may never think to ask about. That understanding develops over time. When lawyers learn: Your customers Revenue model Technology stack Growth strategy Ownership structure They can provide more strategic guidance. That guidance becomes increasingly valuable as the company grows. Legal Risk Systems Help Prevent Founder Disputes Every startup begins with optimism. Very few founders launch businesses expecting future conflict. Yet growth changes circumstances. People change jobs. People relocate. Personal priorities shift. Ownership expectations evolve. Without clear systems governing these transitions, disagreements become personal. Strong startup systems are established: Ownership rules Vesting schedules Decision authority Exit procedures Compensation expectations The goal is not distrust. The goal is clarity. Good agreements preserve relationships because they remove ambiguity. Legal Risk Systems and Specialized Expertise Crowley emphasized the importance of finding specialists rather than generalists. Technology businesses face unique challenges involving: Software ownership Licensing Intellectual property Data protection Investment structures Specialized attorneys encounter these issues regularly. As a result, they often identify risks faster and provide more practical solutions. This mirrors what happens in software development. When a company needs cybersecurity expertise, it seeks specialists. Legal guidance should follow the same principle. Creating an Annual Legal Review Process One practical idea discussed was maintaining regular communication with legal advisors. Many founders wait until a crisis appears. A better approach is creating an annual review process. Topics might include: New business risks Contract changes Hiring plans Funding opportunities Intellectual property developments These conversations often uncover issues while they remain manageable. That proactive mindset transforms legal support from emergency response into strategic planning. Schedule an annual legal review the same way you schedule financial planning sessions. Conclusion Strong businesses are built on repeatable systems. The same principle applies to risk management. Effective Legal Risk Systems combine professional guidance, documented processes, ongoing reviews, and responsible use of AI. Founders who build these systems early gain more than protection—they gain confidence that their company can grow without being undermined by avoidable mistakes. Legal success is rarely about reacting faster. It is about preparing earlier. Stay Connected: Join the Developreneur Community
In this episode of The Lead, host Robert Schaller, DO, FHRS, is joined by Tina Baykaner, MD, MPH, and Maulin Shah, MD, to discuss the journal article, Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial. Together, they review the study's long-term follow-up findings and explore device-related complications associated with transvenous and subcutaneous defibrillator therapy. Learning Objectives: Review the long-term follow-up results of the PRAETORIAN-XL Trial comparing transvenous and subcutaneous defibrillator therapy. Discuss device-related complications associated with transvenous and subcutaneous implantable defibrillator systems. Examine the clinical considerations of defibrillator therapy selection based on long-term device-related outcomes. Host: Robert Schaller, DO, FHRS Guests: Tina Baykaner, MD, MPH and Maulin Shah, MD Disclosures: R. Schaller Honoraria/Speaking/Consulting Fee: Philips, Abbott Medical Officer/Trustee/Director/Committee Chair/Other Fiduciary Role: Imricor Other Financial Relationship: Other T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific M Shah No relevant disclosures
Most technology entrepreneurs spend months refining code, building products, and solving technical challenges. Yet a strong Startup Legal Foundation is often the difference between building a sustainable company and creating a future legal problem. In this conversation with attorney and former Johnson & Johnson Assistant General Counsel Phil Crowley, the discussion focused on a reality many developers overlook: businesses rarely fail because of technology alone. Often, the problems emerge from legal structures, ownership disputes, contracts, intellectual property protection, and decisions made long before revenue arrives. Who Is Phil Crowley? Phil Crowley is the Founder and Managing Partner of Crowley Law LLC. Before launching his own practice, he spent approximately three decades as Assistant General Counsel at Johnson & Johnson, working closely with business leaders, innovators, and technology-focused organizations. His background is particularly unique because he began his professional career as a research physicist before transitioning into law. That combination enables him to bridge the communication gap that often exists between technical founders and legal professionals. Crowley now focuses on helping technology entrepreneurs commercialize innovation while avoiding common legal mistakes that can derail growth. Follow Phil on LinkedIn: https://www.linkedin.com/in/philcrowleynjny/ Why a Startup Legal Foundation Matters Before Revenue Many founders treat legal work as something to address after customers arrive. That approach creates risk. The reality is that every startup begins making legal decisions from day one: Who owns the intellectual property? How is ownership divided? What happens if a founder leaves? Who can sign contracts? How are contractors handled? What entity owns the software? These decisions influence future funding opportunities, acquisitions, and partnerships. A company can have a brilliant product and still become difficult to invest in if ownership questions remain unresolved. Investors often evaluate risk before opportunity. Legal uncertainty increases risk immediately. Startup Legal Foundation and Founder Agreements One of the strongest themes from the discussion was the importance of written agreements between founders. Many startups begin as conversations between friends. The problem is that friendships and business responsibilities rarely remain static. As companies grow: People relocate Career priorities change Family responsibilities increase Contributions become uneven Without written agreements, disagreements become emotional instead of objective. A founder who contributed heavily during the early stages may feel entitled to ongoing ownership. Another founder may feel burdened by carrying the company forward. Neither perspective is necessarily wrong. The issue is that expectations were never documented. A well-designed founder agreement creates clarity before conflict exists. Startup Legal Foundation Creates Predictability When ownership structures are documented early: Expectations become visible Responsibilities become clear Future disputes become easier to resolve Investors gain confidence This isn't about preparing for failure. It's about preparing for growth. Protecting Intellectual Property Before It Becomes Valuable Many technical founders assume intellectual property protection can wait until revenue arrives. Crowley highlighted why this assumption creates problems. Software, inventions, processes, algorithms, and technical innovations often represent the most valuable assets inside a startup. Yet ownership can become surprisingly complicated. Questions emerge, such as: Did a contractor build part of the system? Was university research involved? Did a founder create code before the company existed? Was confidential information publicly disclosed? These situations can weaken ownership claims. For technology companies, intellectual property isn't simply a legal asset. It becomes the foundation of company value. If ownership is unclear, the company's market value may decrease significantly, regardless of product quality. Startup Legal Foundation Requires the Right Legal Partner Another important takeaway was Crowley's perspective on choosing legal counsel. Many entrepreneurs focus solely on finding a lawyer. The better objective is finding a lawyer who understands the business. The best legal advisors don't simply explain laws. They help founders understand consequences. That distinction matters. A lawyer who understands startup operations can help founders evaluate: Entity selection Ownership structures Investor agreements Commercial contracts Growth risks The relationship becomes strategic rather than transactional. Startup Legal Foundation Benefits from Industry Specialists Not all legal expertise is interchangeable. A lawyer specializing in technology startups understands issues that general practitioners may rarely encounter. That specialization often leads to: Better guidance Faster solutions Lower long-term costs Stronger protection The goal isn't finding the biggest law firm. It's finding the right expertise. Ask other founders which legal professionals they trust. Personal recommendations often outperform online searches. Learning from Accelerators and Startup Networks Crowley also emphasized the value of startup accelerators and mentorship programs. Many founders assume they must figure everything out themselves. That mindset slows growth. Accelerators often provide access to: Legal advisors Business mentors Funding networks Operational guidance Experienced entrepreneurs These ecosystems exist because communities benefit when startups succeed. Founders who leverage these resources gain access to lessons that would otherwise take years to learn. Conclusion Technology founders naturally focus on building products. But products alone do not create durable companies. A strong Startup Legal Foundation helps protect intellectual property, clarify ownership, strengthen contracts, and reduce avoidable risk. The legal decisions made during the earliest stages of a company frequently determine how easily that company can scale, attract investment, and survive unexpected challenges. The strongest startups aren't just built on innovation. They're built on a foundation capable of supporting innovation long after launch. Stay Connected: Join the Developreneur Community
This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Hey Hey Poison Friends! We are bringing you part 2 of our look into Johnson & Johnson, and the drama is only escalating. We are discussing the expensive end to their use of talc in baby powders as well as the damage that it did to numerous women and likely others exposed to it. J&J apparently learned nothing from this, however. When people began dying of liver failure after taking too much Tylenol (acetaminophen) or because they had been moderate drinkers before taking it, they did their best to hide the facts from the public. When the FDA asked them to put a warning on Tylenol for its possible effects on the liver, they fought back for years. They made hundreds of millions of dollars on Tylenol, even though it was over the counter, and it was at one point the highest cause of liver failure in the US and in Britain. Then there was the infant's vs children's versions. In the midst of all of this, we need to look into their history of wooing doctors and politicians into their pockets as well as how their agenda for more money has led to bankruptcies and deaths across America for decades. They are not the only ones, and don't worry, we'll get to them too...Thank you to all of our listeners and supporters! We truly appreciate you all! Please feel free to leave a comment or send us a DM!Patreon:patreon.com/thepoisonersalmanacMerch-https://poisonersalmanac.com/The Poisoner's Almanac IG-https://www.instagram.com/poisoners_almanac?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==
What if a doctor tells you there is nothing more they can do to fix your heart blockages, and you've run out of options? In this episode of The Heart of Innovation, hosts Kym McNicholas and Interventional Cardiologist Dr. John Phillips introduce you to EECP (Enhanced External Counterpulsation)—a powerful, non-invasive "Hail Mary" technology that has been saving cardiac patients for decades but remains drastically underutilized in mainstream medicine. In this deep-dive discussion, the team is joined by world-renowned cardiologist Dr. Richard Brown (consultant for Flow Therapy and former head of Johnson & Johnson's Save Legs, Change Lives program) and Jack Clifford, a cardiovascular patient and advocate who famously refused bypass surgery and used EECP to get back to running marathons.
"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about immunomodulators. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 12, 2027. Daniel Verina is on the speakers' bureau for Johnson & Johnson, GlaxoSmithKline, and Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of immunomodulators to treat cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 386: Interprofessional Navigation and the Oral Anticancer Medication Care Compass Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy ONS Voice articles: Maintain Oral Adherence With ONS Guidelines™ Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Sexual Considerations for Patients With Cancer Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Symptom Intervention resource: Peripheral Neuropathy Risk Evaluation and Mitigation Strategies (REMS) Lenalidomide Pomalidomide Thalidomide International Myeloma Foundation: Using Immune Therapy to Fight Multiple Myeloma International Myeloma Society Multiple Myeloma Research Foundation: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We definitely want the diagnosis of multiple myeloma before initiating these drugs. We're going to look at serum protein electrophoresis. We want to make sure that we know the patient has serum free light chains and myeloma proteins to really confirm their disease. Plus, a bone marrow biopsy." TS 7:21 "Each immunomodulator has slightly different side effects. Thalidomide's biggest side effects are constipation, weakness, fatigue, somnolence, peripheral neuropathy, mood swings, hand tremors, and depression. With each generation, less of the side effects actually occurred. Most of lenalidomide's side effects, not discounting the deep vein thrombosis, are pancytopenia—the neutropenia, the anemia, and the thrombocytopenia. [The side effects] are very similar in pomalidomide." TS 15:40 "The REMS program is critical for oral immunomodulator therapies—thalidomide, pomalidomide, and lenalidomide. It was developed due to the risk of developing embryofetal toxicities. ... It is mandatory testing and counseling, so all females of reproductive potential must have two negative pregnancy tests prior to starting the therapy and then monthly pregnancy tests while on the therapy alone. Again, they must use two forms of effective contraceptives or abstain from heterosexual sex four weeks prior, during, and after. And the same thing for men. I focus on that because males may say, 'I have a vasectomy.' These therapies tend to bind to the semen. So, males must still use a latex or synthetic condom during any sexual contact with a female of reproductive potential, even if they did have a vasectomy." TS 18:31 "The capsule itself cannot be chewed, crushed, or opened. I bring that up because as healthcare professionals, we have educated our patients. If it's difficult to swallow capsules or tablets, we've always said to them, 'Oh, don't worry, just crush it into applesauce or open it up and sprinkle it on your mashed potatoes.' But because of this embryofetal toxicity, I advise my patients not to open the capsule. If they can't swallow it for any reason, they have a sore throat or they're just unable to, then [we tell them] to hold the therapy and then call us." TS 22:49 "We spoke about three generations already, but there's actually a fourth generation [of immunomodulators]. They're called cereblon E3 ligase modulators(CELMoDs). They're still in clinical trials but really showing promise in the therapy of myeloma. They're showing very good affinity to cereblons, just like the immunomodulators do. I think, in all cancer therapies, as newer generations come out or newer therapies move forward, some of the older generations might move aside, but they get integrated later on. So I don't think [immunomodulators] will disappear totally, but they will probably be modified." TS 36:39
What does resilience really look like? I meet many professionals today who are navigating wave after wave of change: Reorganisations, shifting priorities, business uncertainty, technological disruption and growing pressure to do more with less have become familiar features of organisational life. Yet while resilience is frequently talked about, it is often misunderstood. In this conversation with Julian Roberts, executive coach, author and host of the Helping Organisations Thrive podcast, we explore what resilience really means for leaders and teams operating in increasingly fragmented environments. After a 20-year career in senior roles at global organisations including Heinz, Yoplait and Johnson & Johnson, Julian founded Julian Roberts Consulting, specialising in helping leaders and teams thrive under pressure. He is the creator of the Team Resilience Diagnostic Tool and author of Weathering the Storm: A Guide to Building Resilient Teams. Together, we discuss why resilience is not about simply pushing through adversity, why 'grit' can sometimes become counterproductive, and how leaders can create the conditions for individuals and teams to navigate uncertainty more effectively. At the heart of this conversation is an important shift in perspective. Resilience is not a fixed trait that some people possess and others lack. It is a capability that can be developed, strengthened and intentionally cultivated, both individually and collectively. What you will learn in this episode: Why uncertainty and constant change are creating new leadership challenges for teams The difference between healthy resilience and what Julian describes as 'toxic resilience' Why resilience is not about simply working harder or pushing through difficulty Practical habits that help strengthen personal resilience, including gratitude, mindfulness and community How leaders can create greater resilience through purpose, meaning and clarity Why understanding the psychology of change helps leaders support people more effectively How diversity of thought strengthens a team's ability to navigate uncertainty and solve complex problems Why healthy challenge and critical thinking are essential leadership capabilities in today's workplace One of the strongest themes throughout this conversation is that resilience is not about individual toughness. Many organisations focus on helping individuals become more resilient, but resilient teams are created through something different. Purpose, trust, psychological safety, challenge, diverse perspectives and strong relationships all play a role in helping teams perform well under pressure. Ultimately, resilience is not about avoiding storms, it is about developing the capability to navigate them with greater clarity, adaptability and confidence. When faced with uncertainty, do you tend to push through harder, or create space to learn, reflect and adapt? What practices could help you strengthen your own resilience and support the resilience of those around you? Resources: Connect with Julian Roberts on LinkedIn: https://www.linkedin.com/in/julesroberts/ Learn more about Julian's book, 'Weathering the Storm': https://www.amazon.co.uk/dp/B0DFTYN2Y2 Listen to Julian Roberts' podcast: https://www.julianrobertsconsulting.com/podcast-1 Find out more about Victoria's leadership and Cultural Intelligence programmes: https://culturecuppa.com/individuals/ Learn more about and buy Victoria's book, Become a Global Leader: https://culturecuppa.com/book/ Follow Victoria on LinkedIn for more strategies, ideas and inspiration:https://www.linkedin.com/in/victoria-rennoldson
This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560 Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives. Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock00:59 Remembering Mike stepping in during a past conference02:12 Mike reflects on filling in and returning to MacStock03:00 Speaker continuity and community expectations04:23 Staying healthy before the conference04:52 Mike introduces his workshop format05:12 Stepping into the role of a digital caretaker06:48 A Microsoft Office upgrade reveals a bigger issue08:39 A family member is caught by a Venmo scam09:19 Managing risks, passwords, and financial access10:11 Using built-in Apple tools instead of advanced services10:25 Safari, Chrome, verification codes, and Apple Passwords10:57 Setting up shared family password folders11:29 Defining digital caretaking12:39 The family “alpha nerd” becomes responsible14:11 Remote tech support challenges and FaceTime troubleshooting16:01 Asynchronous support, screenshots, and remote access tools17:57 Older adults as prime targets for scammers18:53 AARP, Craig Newmark, and scam-interruption resources19:51 Gift cards, retail workers, and scam warning signs20:35 Deepfakes, safe words, and trusted contacts21:40 Fake profiles and stolen valor scams22:48 Protecting family members from criminal targeting23:25 Romance scams, business scams, and phishing tactics25:02 Keeping loved ones safe without burning out26:09 The Beekeeper as a scam-awareness example27:07 Recommended resources and My Mother's Money28:18 Financial preparedness and how quickly gaps appear29:39 Using AI tools to find validated resources30:18 Why this workshop may matter to everyone31:02 The future reversal of helper and helped33:00 Balancing safety, respect, and autonomy34:00 Managing support while preserving dignity36:23 Mike's MacStock discount code37:01 Registering for MacStock and planning ahead38:14 Where to find Mike T. Rose and The Aftershow39:29 Mike's social channels and listener acknowledgments40:17 Remembering John Martellaro and Chuck La Tournous41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s.Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce.Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support: Become a MacVoices Patron on Patreon http://patreon.com/macvoices Enjoy this episode? Make a one-time donation with PayPal Connect: Web: http://macvoices.com Twitter: http://www.twitter.com/chuckjoiner http://www.twitter.com/macvoices Mastodon: https://mastodon.cloud/@chuckjoiner Facebook: http://www.facebook.com/chuck.joiner MacVoices Page on Facebook: http://www.facebook.com/macvoices/ MacVoices Group on Facebook: http://www.facebook.com/groups/macvoice LinkedIn: https://www.linkedin.com/in/chuckjoiner/ Instagram: https://www.instagram.com/chuckjoiner/ Subscribe: Audio in iTunes Video in iTunes Subscribe manually via iTunes or any podcatcher: Audio: http://www.macvoices.com/rss/macvoicesrss Video: http://www.macvoices.com/rss/macvoicesvideorss
The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives. Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock 00:59 Remembering Mike stepping in during a past conference 02:12 Mike reflects on filling in and returning to MacStock 03:00 Speaker continuity and community expectations 04:23 Staying healthy before the conference 04:52 Mike introduces his workshop format 05:12 Stepping into the role of a digital caretaker 06:48 A Microsoft Office upgrade reveals a bigger issue 08:39 A family member is caught by a Venmo scam 09:19 Managing risks, passwords, and financial access 10:11 Using built-in Apple tools instead of advanced services 10:25 Safari, Chrome, verification codes, and Apple Passwords 10:57 Setting up shared family password folders 11:29 Defining digital caretaking 12:39 The family "alpha nerd" becomes responsible 14:11 Remote tech support challenges and FaceTime troubleshooting 16:01 Asynchronous support, screenshots, and remote access tools 17:57 Older adults as prime targets for scammers 18:53 AARP, Craig Newmark, and scam-interruption resources 19:51 Gift cards, retail workers, and scam warning signs 20:35 Deepfakes, safe words, and trusted contacts 21:40 Fake profiles and stolen valor scams 22:48 Protecting family members from criminal targeting 23:25 Romance scams, business scams, and phishing tactics 25:02 Keeping loved ones safe without burning out 26:09 The Beekeeper as a scam-awareness example 27:07 Recommended resources and My Mother's Money 28:18 Financial preparedness and how quickly gaps appear 29:39 Using AI tools to find validated resources 30:18 Why this workshop may matter to everyone 31:02 The future reversal of helper and helped 33:00 Balancing safety, respect, and autonomy 34:00 Managing support while preserving dignity 36:23 Mike's MacStock discount code 37:01 Registering for MacStock and planning ahead 38:14 Where to find Mike T. Rose and The Aftershow 39:29 Mike's social channels and listener acknowledgments 40:17 Remembering John Martellaro and Chuck La Tournous 41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s. Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce. Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support: Become a MacVoices Patron on Patreon http://patreon.com/macvoices Enjoy this episode? Make a one-time donation with PayPal Connect: Web: http://macvoices.com Twitter: http://www.twitter.com/chuckjoiner http://www.twitter.com/macvoices Mastodon: https://mastodon.cloud/@chuckjoiner Facebook: http://www.facebook.com/chuck.joiner MacVoices Page on Facebook: http://www.facebook.com/macvoices/ MacVoices Group on Facebook: http://www.facebook.com/groups/macvoice LinkedIn: https://www.linkedin.com/in/chuckjoiner/ Instagram: https://www.instagram.com/chuckjoiner/ Subscribe: Audio in iTunes Video in iTunes Subscribe manually via iTunes or any podcatcher: Audio: http://www.macvoices.com/rss/macvoicesrss Video: http://www.macvoices.com/rss/macvoicesvideorss
This Day in Legal History: The Indian Citizenship Act of 1924On this day in 1924, President Calvin Coolidge signed the Indian Citizenship Act, also called the Snyder Act, declaring that all Native Americans born within the territorial limits of the United States were U.S. citizens. It is one of those laws that sounds, in retrospect, like it cannot possibly have been necessary — and yet it was. For most of the country's first 150 years, the federal government treated Native people as members of separate sovereign nations whose status under American law was, at best, ambiguous. Earlier vehicles for citizenship — the Fourteenth Amendment, the Dawes Act, military service in World War I — had reached only some Native people, and a string of Supreme Court decisions had taken the position that being born inside the United States to a member of a tribe did not, on its own, make a person a citizen.The Snyder Act fixed that with a single sentence.What it did not fix was voting: many states continued to bar Native citizens from the ballot for decades afterward, on a variety of pretexts that were eventually struck down one by one. The Act also did not affect tribal citizenship — Native people are dual citizens of their tribe and the United States, which is part of why federal Indian law continues to occupy a separate doctrinal universe. June 2 is a quietly important date on the calendar of American citizenship, and a reminder that the seemingly obvious questions of who counts as an American have, for long stretches of our history, not been obvious at all.Florida Attorney General James Uthmeier announced Monday that his office has filed a civil lawsuit against OpenAI and its CEO Sam Altman, arguing that the company is misleading parents about the safety of ChatGPT and pointing to incidents in which young users were allegedly nudged toward violence by the chatbot. The complaint follows a criminal investigation Uthmeier's office opened in April, after a deadly mass shooting at Florida State University in 2025 that the AG says ChatGPT helped facilitate. Florida is asking for civil penalties and an order forcing OpenAI to redesign the product, including adding meaningful parental controls.The legal angle here is essentially a state consumer-protection theory: a state attorney general claiming that the company's marketing of a product as safe-for-kids is deceptive, and that the company is therefore on the hook under the state's unfair-trade laws. Whether that survives a motion to dismiss is going to depend a lot on whether the court treats ChatGPT as a “product” in the traditional sense — software has, for decades, gotten more leeway than physical products under product-liability law, and Section 230 of the federal Communications Decency Act has historically immunized platforms for what users post.The new wrinkle is that generative AI doesn't fit neatly into either bucket — ChatGPT produces its own output rather than hosting somebody else's — and several courts are now beginning to grapple with that distinction. Expect this case to be one of the early test cases for how AI companies get sued in the U.S.Florida AG Sues OpenAI, Says ChatGPT Spurs Violence | Law360The Supreme Court on Monday declined to hear an appeal from asbestos victims who had challenged a corporate bankruptcy tactic known as the “Texas Two-Step” — leaving in place a Fourth Circuit ruling that lets companies use the maneuver to corral mass-tort claims into bankruptcy court.The Two-Step works like this: a healthy company splits itself into two using a Texas state-law provision that allows divisional mergers, dumps its asbestos or talc or opioid liabilities into the newly created spinoff, and then puts only the spinoff into Chapter 11. The result is that injury claimants get herded into a bankruptcy proceeding where their leverage is sharply limited, even though the parent company that actually caused the harm is still solvent and operating.The case the Supreme Court turned away involved Bestwall, a spinoff of Georgia-Pacific that has been in Chapter 11 since 2017. The Third Circuit threw out a similar Johnson & Johnson talc-unit bankruptcy in 2023 on the ground that the spinoff wasn't actually in financial distress, but the Fourth Circuit went the other way in this case, and the Supreme Court's denial of review leaves that split standing for now. The bigger picture: a powerful settlement-shaping tool stays on the menu for corporate defendants facing waves of mass-tort litigation, and the next big talc, opioid, or asbestos defendant looking to manage a docket of claims now knows the Two-Step is at least available in the Fourth Circuit.Justices Won't Hear Challenge To ‘Texas Two-Step' Ch. 11 | Law360A group of IKEA customers filed a proposed class action against the Swedish retailer Monday in U.S. federal court, arguing that they overpaid for furniture during the period when President Trump's import tariffs were in effect — tariffs that the Supreme Court has since struck down — and that they are entitled to a share of the refunds the company will now collect from the federal government. It is one of the first big consumer-side cases to follow the Supreme Court's tariff ruling, and the legal theory is novel: importers paid the tariffs, then passed those costs through to consumers in the form of higher sticker prices, and now that the government is sending refunds back to importers, the customers who effectively bore the cost are asking for a piece of that money.Some major shippers like FedEx and UPS have already publicly committed to passing tariff refunds back to their customers; IKEA, the suit alleges, has not. Whether the claim survives depends largely on whether the court is willing to treat the relationship between retailer and customer as something like a constructive trust or unjust enrichment, rather than an arm's-length sale at a final price. If even one of these cases succeeds, expect copycat suits against every other large importer that quietly built tariff costs into retail prices over the last several years.IKEA customers sue for share of Trump tariff refunds | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
Eric Ries is the entrepreneur and author of The Lean Startup, whose work helped software founders validate ideas faster and build companies without making huge bets upfront. After years helping startups, large companies, and governments apply Lean Startup principles, Eric built the Long-Term Stock Exchange and turned his attention to a bigger question: Why do so many successful companies lose their way? In our conversation, Eric explains the idea of "financial gravity"—the hidden force that pushes companies toward short-term financial thinking as they grow. He shares cautionary stories of companies like Whole Foods, Johnson & Johnson, Silicon Valley Bank, and Costco to show how scaling, investors, boards, and even employees can gradually erode trust, mission, and long-term value. Eric's new book, Incorruptible Why Good Companies Go Bad…and How Great Companies Stay Great, offers practical ways founders can protect the soul of their companies before it's too late--even when they don't have big outside investors. He explains why founders should explicitly codify their mission into governance structures, why trust is the most underrated asset in business, and how practical founders can retain optionality while building valuable companies that endure. Drawing on two decades of work with founders, CEOs, and investors, Eric Ries reveals the forces that make companies vulnerable to destruction from within and without. Then he offers solutions that safeguard against them for the long-term. Incorruptible is the blueprint for companies that will prosper and endure without losing their soul. Key Takeaways Financial Gravity - Every growing company faces pressure toward short-term financial thinking—even without outside investors. Trust Compounds - Companies that earn trust with customers and employees often outperform financially over the long term. Founder Regret - Many founders regret selling because the mission, culture, and soul of the company disappear. Mission Protection - Values on a wall aren't enough—founders need legal and governance structures to preserve mission. Question Best Practices - Many accepted business practices optimize short-term profits while destroying long-term value. Think Long-Term - Practical founders have more optionality when they intentionally design companies to endure. Quote from Eric Ries, Author of the Lean Startup "People have woken up to this reality. Given where we're at, if you can create a bootstrap company, if you can maintain control, it doesn't make you completely safe. The problem is actually not investors, but financial thinking. "So I tell a bunch of stories in my book (Incorruptible) of companies where the issue wasn't investors, but their own employees. You start to bring in professional managers. You start to bring in a CFO, and the CFO has that extractive mindset, or even worse. "Financial gravity is one of the most underrated concepts in business. It is like trying to direct our attention away from the surface characteristics of an organization to the deeper forces that act on it. Your business model, strategy, vision, culture, these things are very important, but they are the things that we have control over. Financial gravity is a force." Links Eric Ries on LinkedIn Eric Ries on Twitter Eric Ries Podcast Incorruptible book on Amazon Podcast Sponsor – Lighter Capital This podcast is sponsored by Lighter Capital. In the last 15 years, Lighter Capital has helped over 600 software and SaaS founders secure simple, non-dilutive financing to grow a little faster—without giving up any precious equity or board seats to investors. Simple debt funding from Lighter Capital can range from $50K to $10 million, with straightforward terms, no personal guarantees or covenants, and up to a 4-year payback period. Go to LighterCapital.com to apply and get a quick pre-qualification. Then talk with their experienced team to create a practical funding plan to achieve your goals. The Practical Founders Podcast Tune into the Practical Founders Podcast for weekly in-depth interviews with founders who have built valuable software companies without big funding. Subscribe to the Practical Founders Podcast using your favorite podcast app or view on our YouTube channel. Get the weekly Practical Founders newsletter and podcast updates at practicalfounders.com. Practical Founders CEO Peer Groups Be part of a committed and confidential group of practical founders creating valuable software companies without big VC funding. A Practical Founders Peer Group is a committed and confidential group of founders/CEOs who want to help you succeed on your terms. Each Practical Founders Peer Group is personally curated and moderated by Greg Head.
One of the largest mass tort litigations in U.S. history is heating up, and this episode breaks down exactly what you need to know. From the collapse of Johnson & Johnson's third bankruptcy attempt to the current push for bellwether trials and remands, attorney Cameron Stephenson of Levin Papantonio gives a candid, insider look at where the talc litigation stands and what plaintiffs, attorneys, and affected individuals can expect in the months ahead. Host Greg is joined by Cameron to unpack the science behind asbestos contamination in talc, the latency period for ovarian cancer and mesothelioma diagnoses, why J&J's litigation tactics have drawn fierce criticism, and what a realistic path to settlement actually looks like. Join Gregg and Cameron on Cut to the Chase as they explore: Why J&J's three bankruptcy attempts were rejected and what that means for plaintiffs The science behind asbestos in talc and how it causes ovarian cancer and mesothelioma What "latent disease" means and why recent diagnoses can still qualify for claims How the MDL remand process works and why it matters for case resolution The current state of state court trials and why plaintiffs have been winning Why J&J attacked Beasley Allen — and what it reveals about their litigation strategy KEY MOMENTS Intro: Talc mass tort litigation overview Post-bankruptcy update: Back in the MDL How the 3 bankruptcies froze all cases Bellwether trial target: Q3/Q4 + active state court cases Can recently diagnosed patients still file? What is a latent disease & why it matters The asbestos-talc connection explained How asbestos gets into talcum powder (the mining process) J&J's defense vs. the evidence against them MDL, remand & Daubert explained in plain English Wave remand strategy: How to pressure J&J Why plaintiffs' attorneys need to coordinate now The $8.9B offer and why it wasn't enough Hope for plaintiffs: Strong science, angry juries How to contact Cameron Stevenson The attack on Beasley Allen, J&J's scorched earth tactics Closing: Don't wait, justice is coming Cameron Stephenson is an attorney at Levin Papantonio, one of the country's leading plaintiffs' litigation firms. With a track record of significant courtroom victories, Cameron holds leadership positions in several of the largest mass tort litigations in the U.S., including the talc/ovarian cancer MDL and the Ozempic litigation. Stephenson is an active advocate for coordination among plaintiffs' counsel in the talc litigation, offering trial school resources, deposition packages, and case preparation support to attorneys across the country. Contact Cameron Stephenson: Phone: (850) 435-7176 Email: cstephenson@levinlaw.com Website: https://levinlaw.com/ Want more insights on leadership, crisis, and the decisions that define careers and companies? Subscribe to Cut to the Chase with Gregg Goldfarb for new episodes every week.
This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Jason Brooks to unpack his journey from serving as a Navy hospital corpsman and working alongside Marines in Iraq to building a successful career across surgical devices, capital equipment, genetic testing, and biotech. Jason shares how his early medical training, military leadership experience, and business background helped him break into medical sales with Johnson & Johnson, what it took to navigate the interview process, and how one career changing offer reshaped his future. He also breaks down the differences between selling in the operating room and selling genetic testing into clinics and hospital systems, why reps need to understand stakeholders beyond the physician, and how culture, strategy, and persistence can define long term success in the industry. This episode is a must listen for anyone looking to break into medical sales, transition between specialties, or understand what it really takes to build a meaningful career in the field. Connect with Jason Brooks: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »
Live from Sin City it's The Majority Report On today's program: While speaking on the Senate floor about Bernie Sanders' resolutions to block the transfer of bulldozers and weapons to Israel, Senator Chris Van Hollen (D-MD) highlights the story of Rachel Corrie, an American killed by an armored Israeli bulldozer. The resolution failed thanks to every single Republican and 7 Democrats - like Chuck Schumer and Kristen Gillibrand. Scott Bessent claims that the tariff refunds are, thanks to the Supreme Court, going to China. Sam hosts a series of interviews with lawyers from the firm Levin Papantonio the Mass Tort Conference in Las Vegas. Glen Ged discusses his firms work on Internation Emergency Economic Powers Act tariff refunds. Peter Mougey joins Sam for an update on his firms work on the opioid epidemic. Chris Tisi joins Sam to discuss a mass tort case involving Johnson & Johnson and the toxicity of talcum powder. Caleb Cunningham really piques Sam interest with his work on infections stemming from dirty scopes used in colonoscopies in a case near to Sam's...heart. Rep. Jared Golden (D-ME) sabotages the war powers act vote. Pete Hegseth recites a prayer that is stolen from Pulp Fiction. Hegseth also went on an antisemitic rant about the media during a pentagon briefing. Tim Pool has a theory about women that really applies to him in an outrageous display of total projection. All that and more To connect and organize with your local ICE rapid response team visit ICERRT.com The Congress switchboard number is (202) 224-3121. You can use this number to connect with either the U.S. Senate or the House of Representatives. Follow us on TikTok here: https://www.tiktok.com/@majorityreportfm Check us out on Twitch here: https://www.twitch.tv/themajorityreport Find our Rumble stream here: https://rumble.com/user/majorityreport Check out our alt YouTube channel here: https://www.youtube.com/majorityreportlive Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! https://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: https://majority.fm/app Go to https://JustCoffee.coop and use coupon code majority to get 10% off your purchase Check out today's sponsors: FAST GROWING TREES: Get 20% off your first purchase. FastGrowingTrees.com/majority SUNSET LAKE: use coupon code 420 to save 30% sitewide at sunsetlakecbd.com The sale ends April 22nd at midnight Eastern time. Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech On Instagram: @MrBryanVokey Check out Matt's show, Left Reckoning, on YouTube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com
© 2020-2026 Ivy Podcast Discovery LLC
